Marker Therapeutics, Inc. (MRKR)
0.8928
0.00 (0.00%)
USD |
NASDAQ |
Nov 06, 16:00
0.9166
+0.02
(+2.67%)
After-Hours: 20:00
Marker Therapeutics Research and Development Expense (Quarterly) : 1.476M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.476M |
| March 31, 2026 | 2.843M |
| December 31, 2025 | 2.141M |
| September 30, 2025 | 2.346M |
| June 30, 2025 | 4.177M |
| March 31, 2025 | 3.135M |
| December 31, 2024 | 5.086M |
| September 30, 2024 | 3.471M |
| June 30, 2024 | 2.335M |
| March 31, 2024 | 2.575M |
| December 31, 2023 | 2.617M |
| September 30, 2023 | 2.045M |
| June 30, 2023 | 2.378M |
| March 31, 2023 | 3.376M |
| December 31, 2022 | 2.182M |
| September 30, 2022 | 3.592M |
| June 30, 2022 | 6.555M |
| March 31, 2022 | 7.026M |
| December 31, 2021 | 8.017M |
| September 30, 2021 | 6.784M |
| June 30, 2021 | 7.35M |
| March 31, 2021 | 5.643M |
| December 31, 2020 | 5.984M |
| September 30, 2020 | 4.804M |
| June 30, 2020 | 4.277M |
| Date | Value |
|---|---|
| March 31, 2020 | 3.817M |
| December 31, 2019 | 3.661M |
| September 30, 2019 | 3.118M |
| June 30, 2019 | 3.152M |
| March 31, 2019 | 2.833M |
| December 31, 2018 | 118.69M |
| September 30, 2018 | 1.877M |
| June 30, 2018 | 1.827M |
| March 31, 2018 | 1.600M |
| December 31, 2017 | 1.436M |
| September 30, 2017 | 1.623M |
| June 30, 2017 | 1.203M |
| March 31, 2017 | 0.9891M |
| December 31, 2016 | 0.4568M |
| September 30, 2016 | 1.109M |
| June 30, 2016 | 1.248M |
| March 31, 2016 | 0.9858M |
| December 31, 2015 | 0.1314M |
| September 30, 2015 | 0.7692M |
| June 30, 2015 | 0.2012M |
| March 31, 2015 | 0.6094M |
| December 31, 2014 | 0.1115M |
| September 30, 2014 | 0.0325M |
| June 30, 2014 | 0.0225M |
| March 31, 2014 | 0.0225M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Rigel Pharmaceuticals, Inc. | 18.27M |
| ACADIA Pharmaceuticals, Inc. | 76.28M |
| Alnylam Pharmaceuticals, Inc. | 408.54M |
| Anika Therapeutics, Inc. | 7.895M |
| Savara, Inc. | 21.95M |